TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00164619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VOICES/VOCES
Description: 45-minute intervention for small groups of African American and Hispanic heterosexual men and women. Group members are same gender and race/ethnicity. View culturally-specific condom promotion video. Facilitated group discussion to build skills in condom use and condom negotiation. Education on condom varieties to overcome participants' personal barriers to condoms use. Distribution of 3 specialty condoms of participant's choice (i.e., different sizes, textures, thicknesses, lubrication, material). \[see Brief Summary above\]

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard STD clinic services
Description: Individual physical exam, STD/HIV tests, treatment as indicated
Study: NCT03708172

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Intermittent TBS (iTBS) rTMS applied to the left Dorsolateral Prefrontal Cortex (DLPFC) + continuous TBS (cTBS) rTMS applied to the right DLPFC. The order will be counterbalanced. Administration of this treatment takes roughly 10 minutes. This treatment will be applied daily, 5 days/week, for 4 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Intermittent TBS (iTBS) rTMS applied to the left Dorsolateral Prefrontal Cortex (DLPFC) + continuous TBS (cTBS) rTMS applied to the right DLPFC. The order will be counterbalanced. Administration of this treatment takes roughly 10 minutes. This treatment will be applied daily, 5 days/week, for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Computer-based cognitive training designed to enhance executive function

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham Cognitive Training
Description: Computer-based inactive sham training
Study: NCT03109158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC-6004
Description: NC-6004 provided by NanoCarrier

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Commercially Available

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Commercially Available
Study: NCT02126449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting mimicking diet
Study: NCT03837704

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IQOS
Description: AAA patients will switch from cigarette smoking to ad libitum IQOS use, with no flavor variant restrictions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette
Description: AAA patients will continue to smoke their cigarettes ad libitum, with no brand restrictions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation
Description: AAA patients who have completely quit smoking will continue to remain abstinent from smoking cigarettes or using any tobacco or nicotine-containing product(s)
Study: NCT03505385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Co-created intervention - Get Ready (GR)
Description: The Get Ready (GR) intervention was delivered one-to-one with the care home resident and a relevant family member during a 12-week period:~1. The familiarisation stage aimed to build a rapport with two long-term achievement goals to sit less and move more with the resident and the family member and consisted of two sessions, one in week 1 (50-60minutes) and the other in week 3 (30-40 minutes).~2. The ramping up stage aimed to review the rapport and reach an achievable consensus with the resident and the family member. It consisted of two sessions, one in week 5 and the other in week 7 (20-30 minutes each).~3. The maintenance stage aimed at integrating behaviours and included two sessions, one in week 9 and the other at week 12 (20-30 minutes each). Sessions 5 and 6 were used to understand how the resident was getting on with their short-term GR goals, facilitating some problem-solving discussions.
Study: NCT00718549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Cladribine will be adminiatered at a dose of 0.12 mg/kg/day as IV infusion on Days 2-4 of each 28-day cycle during induction phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administred at a dose of 250 mg/m\^2/day as IV infusion over 15-30 minutes on Days 2-4 of each 28-day cycle during induction phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered at a dose of 375 mg/m\^2 as IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\^2 as IV infusion on Day 1 of Cycles 2-6 during induction phase. Rituximab will be administered at a dose of 375 mg/m\^2 as IV infusion on Day 1 of each 12-week cycle during maintenance phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered at a dose of 375 mg/m\^2 as IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\^2 as IV infusion on Day 1 of Cycles 2-6 during induction phase. Rituximab will be administered at a dose of 375 mg/m\^2 as IV infusion on Day 1 of each 12-week cycle during maintenance phase.
Study: NCT01353508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: 200 mg and 400 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: 200 mg and 400 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: 200 mg and 400 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: 200 mg and 400 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 160 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 160 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 160 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 160 mg tablets
Study: NCT01951079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-amniotic injection of DIGOXIN
Study: NCT03373981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: repetitive transcranial magnetic stimulation
Study: NCT03366051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Node Mapping
Description: At least one sentinel node should be retrieved in both hemipelvis. If no sentinel node is found in one hemipelvis, a side specific lymphadenectomy will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel Node Mapping
Description: At least one sentinel node should be retrieved in both hemipelvis. If no sentinel node is found in one hemipelvis, a side specific lymphadenectomy will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lymphadenectomy
Description: Systematic Pelvic and Para-Aortic Lymphadenectomy
Study: NCT00701090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: Sitagliptin 100 mg q.d. (q.d. = once daily); Duration of Treatment: 30 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: glimepiride
Description: glimepiride 1 mg per day to be up-titrated (up to week 18 of the double-blind treatment period) as considered appropriate by the investigator, based upon the results of patient's self blood glucose monitoring (SBGM). The maximum dose of glimepiride must not be higher than 6 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: open-label metformin
Description: open-label metformin oral tablets (≥1500 mg/day) in addition to Glimepiride or Sitagliptin treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: open-label metformin
Description: open-label metformin oral tablets (≥1500 mg/day) in addition to Glimepiride or Sitagliptin treatment.
Study: NCT01576172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT03623451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Medicine Formula
Description: Chinese Medicine Formula, composed of American ginseng 10g, Poria cocos 15g, bighead atractylodes rhizome 20g, Astragalus mongholicus 30g, Crataegus pinnatifida Bunge 20g, Salvia miltiorrhiza Bge. 20g, Pericarpium Citri Reticulatae 10g will be decocted and packaged into vacuum packs by the pharmaceutical department of First Affiliated Hospital, Heilongjiang University of Chinese Medicine (140 mL/pack). Subjects will take 2 packages per day for three months.
Study: NCT00381563

Intervention type: DEVICE
Group type: OTHER
Intervention: Patellofemoral realigning knee brace
Description: Knee brace that changes the tracking of the patella over the femur bone

Intervention type: DEVICE
Group type: OTHER
Intervention: Patellofemoral realigning knee brace
Description: Knee brace that changes the tracking of the patella over the femur bone

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-aligning knee brace
Description: Knee brace that does not change the tracking of the patella over the femur bone

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-aligning knee brace
Description: Knee brace that does not change the tracking of the patella over the femur bone
Study: NCT04532736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emthexate
Description: After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednol
Description: After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate
Description: After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
Study: NCT03019250

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Colostrum
Description: Enteral colostrum 20g/day powdered colostrum to be mixed in with water and given via nasogastric tube q4 hrs.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin mixed with water given via NG tube Q 4 hours.
Study: NCT02785965

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Disposable, single-use, sterilized stainless-steel needles (Yunlong, Beijing, China; length 40/100 mm, diameter 0.30 mm) are inserted into waist, bilaterally. All of the six points are located in the Dai Meridian route corresponding to the ovaries. Four needles, 0.25mm in diameter and 25mm in length, are also placed in distal acupuncture points which are located in the feet and lower arms to enhance local points' effects. Acupuncture needles of 0.3mm in diameter and 100mm in length are inserted into GB26(Daimai) with a depth of 25-65mm by an angle of 15°, following the path of Dai Meridian (towards medial and downside). The other needles are inserted vertically into the acupoints with a depth of 10-30mm, depending on the thickness of muscles. Electro-acupuncture is applied to both sides of GB26 and ST25(Tianshu): cathode is connected to GB26; anode to ST25. Needles are stimulated electrically with low frequency (2 Hz) for 20 min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle modification
Description: The diet restricts patients to 1400 calories a day for 12 weeks.The exercise included 12 weeks of aerobic exercise in moderate level (60 to 70% of maximum heart rate), for 3 sessions a week, each session for 60 min. The exercises included: Warning up: 10 min, main phase (aerobic exercise): 40 min and cooling down: 10 min. Polar Pulse measuring device from China was used to control the intensity of the exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle modification
Description: The diet restricts patients to 1400 calories a day for 12 weeks.The exercise included 12 weeks of aerobic exercise in moderate level (60 to 70% of maximum heart rate), for 3 sessions a week, each session for 60 min. The exercises included: Warning up: 10 min, main phase (aerobic exercise): 40 min and cooling down: 10 min. Polar Pulse measuring device from China was used to control the intensity of the exercises.
Study: NCT01274936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishe Pill
Description: Pill, 3.75 g, twice per day, four weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Qishe Placebo
Description: Pill, 3.75 g, twice per day, four weeks
Study: NCT04559945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aveir VR Leadless Pacemaker System
Description: Patients will undergo an attempted leadless pacemaker implant
Study: NCT03056560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TakeCARE (video bystander program)
Description: brief video encouraging active responses to high-risk situations for campus violence
Study: NCT01106495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced External Counterpulsation (EECP)
Description: EECP one hour per day, 5 hours a week for a total of 35- 36 hours over a 7 week period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 40 mg/d for 7 weeks as the guideline- driven standard medical treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 40 mg/d for 7 weeks as the guideline- driven standard medical treatment
Study: NCT00473551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 intravenously over several hours on Day -13, followed by 1000 mg/m\^2 intravenously on Days -6, 1, and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg intravenously over two hours on Day -6, immediately following Fludarabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 intravenously over 30 minutes once per day for 4 days, starting Day -6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 10 mg/kg continuous intravenous infusion for 4 hours for total of 6 doses (24 hours) following Cyclophosphamide.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Treatment
Description: 2Gy Total body radiation day before transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation (SCT)
Description: Allo CD34+ Selected SCT/Infusion of stem cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: 6 mg by mouth on day -2 followed by 2 mg daily from day -1 through day +7.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anti-third Party Cytolytic T-lymphocytes (CTL)
Description: Intravenous infusion of anti-third party CTL.
Study: NCT00510991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nippv
Study: NCT01433757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin
Description: Ampicillin will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of Ampicillin will be given to the patient, to be taken in the same manner as described above.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: The sugar pill will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of the sugar pill will be given to the patient, to be taken in the same manner as described above.
Study: NCT00851682

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI scan
Description: Each patient will undergo one, contrast-enhanced MRI scan prior to his planned, standard of care procedure, either radical prostatectomy or brachytherapy, depending on the study arm. Patients will be randomized to be imaged with either a phased array body coil or an endorectal coil.

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI scan
Description: Each patient will undergo one, contrast-enhanced MRI scan prior to his planned, standard of care procedure, either radical prostatectomy or brachytherapy, depending on the study arm. Patients will be randomized to be imaged with either a phased array body coil or an endorectal coil.
Study: NCT03570372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based treatment for adults with autism spectrum
Description: Internet-based CBT. The intervention includes 18 modules focusing on: Psychoeducation, individual goal setting, behavioral change, management strategies and stress management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation about autism spectum disorder
Description: Self-studies by reading the book What does the disability mean ?: Living with autism / Asperger syndrome. Project Empowerment (2004), by Norrö \& Swing Åström, as well as a book of biographical stories of people who have ASD. The first book will be read during the first half of the project, and the second will be in the second half.
Study: NCT00806676

Intervention type: DRUG
Group type: OTHER
Intervention: Gardasil® Vaccine (FDA-approved vaccination regimen)
Description: Standard Gardasil® 3-dose regimen (0.5 mL/dose; doses at 0, 2 and 6 months) delivered to females with chronic kidney disease 9-21 years of age.

Intervention type: DRUG
Group type: OTHER
Intervention: Gardasil® Vaccine (FDA-approved vaccination regimen)
Description: Standard Gardasil® 3-dose regimen (0.5 mL/dose; doses at 0, 2 and 6 months) delivered to females with chronic kidney disease 9-21 years of age.

Intervention type: DRUG
Group type: OTHER
Intervention: Gardasil® Vaccine (FDA-approved vaccination regimen)
Description: Standard Gardasil® 3-dose regimen (0.5 mL/dose; doses at 0, 2 and 6 months) delivered to females with chronic kidney disease 9-21 years of age.
Study: NCT04454697

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tissue retractors
Description: Patients receive a tissue retractor to spare healthy tissue during the course of radiation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tissue retractors
Description: Patients receive a tissue retractor to spare healthy tissue during the course of radiation
Study: NCT03165435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV-MG01
Description: 3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
Study: NCT04608760

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meksibel
Description: 2 ml solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meksibel
Description: 2 ml solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meksibel
Description: 2 ml solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meksibel
Description: 2 ml solution
Study: NCT02822950

Intervention type: DRUG
Group type: OTHER
Intervention: Ceftazidime/avibactam
Description: Ceftazadime/avibactam dosing in ICU patients
Study: NCT03406143

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CGF injection
Description: CGF injection subdermally to expanded skin at the density of 0.02ml/cm2.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Saline will be injected into expanded skin
Study: NCT00684450

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Titration protamine
Description: 10. Study group: celite ACT will be performed every 3 minutes during protamine infusion until ACT values suggest reach of a plateau (defined as 2 similar ACT values, within 10% variability, and ACT ≤ to 160 seconds.), time at which infusion will be stopped. 2cc of blood is required per ACT test, for a maximum total of 10cc.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard administration of protamine
Description: 1.3 mg of Protamine for 100u héparine
Study: NCT00105144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caspofungin
Description: IV
Study: NCT03161288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KY1005
Description: A human anti-OX40 ligand monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KY1005
Description: A human anti-OX40 ligand monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo
Study: NCT01958788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioural Treatment
Description: 12 weekly sessions of individual cognitive-behavioural treatment (CBT) targeting intolerance of uncertainty.
Study: NCT03526354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole 4mg daily for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Current antipsychotic medication for 12 weeks
Study: NCT02378220

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenetic testing
Description: Pharmacogenetic testing via YouScript® Personalized Prescribing System